Objective To investigate the application effect and feasibility of the combination therapy of carboplatin and albumin bound paclitaxel (Nab-paclitaxel,Nab PTX) in elderly patients with recurrent ovarian cancer. Method:A retrospective study was conducted on 90 elderly patients with recurrent ovarian cancer admitted to our hospital from March 2021 to March 2024. They were divided into a control group (treated with carboplatin+paclitaxel, n=45) and an observation group (treated with carboplatin+albumin bound paclitaxel (Nab PTX)) according to the treatment method, n=45], Results: Observe the treatment efficacy, serum tumor markers, and quality of life of all patients, and evaluate the safety of treatment. The total effective rate of the observation group after chemotherapy was 75.56%, which was higher than the control group"s 51.11%, and the disease control rate of the observation group was 91.11%, which was higher than 73.33%, P＜0.05； There was no significant difference in the levels of(Recombinant High Mobility Group AT Hook Protein 2,HMGA2), (Matrix Metallopeptidase 2,MMP-2),(Vascular Endothelial Growth Factor,VEGF), and( Carbohydrate Antigen 125,CA125) among all patients before chemotherapy, P>0.05, After chemotherapy, the above indicators in the observation group were lower than those in the control group, P＜0.05；Before chemotherapy, there were no differences in cognitive function, social function, emotional function, physical function, and role function among all patients, P>0.05, Six months after chemotherapy, the above scores were higher in the observation group than in the control group, P＜0.05； After chemotherapy, there was no significant difference in the incidence of adverse reactions between the observation group (11.11%) and the control group (13.33%), P>0.05。 Conclusion The combination therapy of Nab PTX and carboplatin has a good intervention effect on elderly patients with recurrent ovarian cancer, which can reduce the levels of serum tumor markers and improve the quality of life after chemotherapy. Compared with conventional clinical drugs, it does not increase the risk of adverse reactions.